Compare ADAM & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADAM | DBVT |
|---|---|---|
| Founded | 2003 | 2002 |
| Country | United States | France |
| Employees | N/A | 90 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 826.7M | 948.8M |
| IPO Year | 2003 | 2014 |
| Metric | ADAM | DBVT |
|---|---|---|
| Price | $10.14 | $14.09 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | $9.17 | ★ $32.04 |
| AVG Volume (30 Days) | ★ 885.3K | 382.0K |
| Earning Date | 04-29-2026 | 05-12-2026 |
| Dividend Yield | ★ 11.87% | N/A |
| EPS Growth | ★ 196.49 | 10.26 |
| EPS | ★ 0.87 | N/A |
| Revenue | N/A | ★ $5,636,000.00 |
| Revenue This Year | N/A | $35.04 |
| Revenue Next Year | $5.08 | $2,360.78 |
| P/E Ratio | $11.68 | ★ N/A |
| Revenue Growth | N/A | ★ 35.77 |
| 52 Week Low | $6.45 | $8.80 |
| 52 Week High | $10.36 | $26.19 |
| Indicator | ADAM | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 72.70 | 45.30 |
| Support Level | $8.61 | $12.75 |
| Resistance Level | N/A | $14.68 |
| Average True Range (ATR) | 0.27 | 0.71 |
| MACD | 0.13 | 0.15 |
| Stochastic Oscillator | 88.84 | 65.07 |
Adamas Trust Inc is an internally-managed REIT for U.S. federal income tax purposes, in the business of acquiring, investing in, financing, and managing mainly mortgage-related single-family and multi-family residential assets. Its objective is to deliver long-term stable distributions to its stockholders over changing economic conditions through a combination of net interest spread and capital gains from a diversified investment portfolio. The company's investment portfolio includes credit-sensitive single-family and multi-family assets.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.